Literature DB >> 25490242

Intravitreal chemotherapy provides control for massive vitreous seeding from retinoblastoma.

Brendan M Lawson, Jarin Saktanasate, Emil Anthony T Say, Carol L Shields.   

Abstract

Treatment of vitreous seeds in retinoblastoma is challenging because of relatively poor chemotherapeutic drug penetration by standard intravenous or intra-arterial routes. Intravitreal monotherapy with melphalan is effective but has a narrow therapeutic window. The authors describe a case of massive vitreous seeding successfully controlled after combination intravitreal chemotherapy using melphalan and topotecan with preserved anatomic outcome. Copyright 2014, SLACK Incorporated.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25490242     DOI: 10.3928/01913913-20141203-05

Source DB:  PubMed          Journal:  J Pediatr Ophthalmol Strabismus        ISSN: 0191-3913            Impact factor:   1.402


  4 in total

1.  Potential of Aqueous Humor as a Surrogate Tumor Biopsy for Retinoblastoma.

Authors:  Jesse L Berry; Liya Xu; A Linn Murphree; Subramanian Krishnan; Kevin Stachelek; Emily Zolfaghari; Kathleen McGovern; Thomas C Lee; Anders Carlsson; Peter Kuhn; Jonathan W Kim; David Cobrinik; James Hicks
Journal:  JAMA Ophthalmol       Date:  2017-11-01       Impact factor: 7.389

2.  Posterior Vitreous Detachment and the Associated Risk of Retinal Toxicity with Intravitreal Melphalan Treatment for Retinoblastoma.

Authors:  Jesse L Berry; Ramon Lee; Luv Patel; Bao Han A Le; John O'Fee; Rima Jubran; Jonathan W Kim
Journal:  Ocul Oncol Pathol       Date:  2018-11-02

Review 3.  Aqueous Humor Markers in Retinoblastoma, a Review.

Authors:  Benjamin K Ghiam; Liya Xu; Jesse L Berry
Journal:  Transl Vis Sci Technol       Date:  2019-04-09       Impact factor: 3.283

4.  TFF1 in Aqueous Humor-A Potential New Biomarker for Retinoblastoma.

Authors:  Maike Anna Busch; André Haase; Natalia Miroschnikov; Annika Doege; Eva Biewald; Nikolaos E Bechrakis; Manfred Beier; Deniz Kanber; Dietmar Lohmann; Klaus Metz; Nicole Dünker
Journal:  Cancers (Basel)       Date:  2022-01-28       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.